AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
AMZN   3,104.00 (-3.00%)
CGC   17.30 (-0.69%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
AMZN   3,104.00 (-3.00%)
CGC   17.30 (-0.69%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
AMZN   3,104.00 (-3.00%)
CGC   17.30 (-0.69%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BA   175.65 (-1.56%)
AAPL   381.91 (-0.46%)
MSFT   207.07 (-3.09%)
AMZN   3,104.00 (-3.00%)
CGC   17.30 (-0.69%)
MU   49.46 (-2.45%)
GE   6.70 (+0.15%)
TSLA   1,497.06 (-3.08%)
F   6.06 (-0.66%)
GILD   76.68 (+0.47%)
DIS   116.22 (-2.61%)
NFLX   525.50 (-4.23%)
BA   175.65 (-1.56%)
Log in

NASDAQ:PTGXProtagonist Therapeutics Stock Price, Forecast & News

$15.17
-1.12 (-6.88 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$15.17
Now: $15.17
$16.38
50-Day Range
$15.38
MA: $16.90
$18.64
52-Week Range
$4.47
Now: $15.17
$19.67
Volume37,980 shs
Average Volume473,455 shs
Market Capitalization$416.11 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company was founded in 2006 and is headquartered in Newark, California.
Read More
Protagonist Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTGX
CUSIPN/A
Phone510-474-0170

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$230,000.00
Book Value$2.94 per share

Profitability

Net Income$-77,190,000.00

Miscellaneous

Employees64
Market Cap$416.11 million
Next Earnings Date8/5/2020 (Estimated)
OptionableNot Optionable

Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

How has Protagonist Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Protagonist Therapeutics' stock was trading at $7.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PTGX shares have increased by 111.9% and is now trading at $15.17. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Protagonist Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Protagonist Therapeutics.

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Protagonist Therapeutics.

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics Inc (NASDAQ:PTGX) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by $0.03. The business had revenue of $3.65 million for the quarter, compared to analysts' expectations of $3.60 million. View Protagonist Therapeutics' earnings history.

What price target have analysts set for PTGX?

5 brokerages have issued twelve-month price targets for Protagonist Therapeutics' shares. Their forecasts range from $28.00 to $33.00. On average, they anticipate Protagonist Therapeutics' stock price to reach $30.60 in the next twelve months. This suggests a possible upside of 101.7% from the stock's current price. View analysts' price targets for Protagonist Therapeutics.

Has Protagonist Therapeutics been receiving favorable news coverage?

Media stories about PTGX stock have been trending very negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Protagonist Therapeutics earned a news sentiment score of -3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Protagonist Therapeutics.

Who are some of Protagonist Therapeutics' key competitors?

What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include Viking Therapeutics (VKTX), Agile Therapeutics (AGRX), TG Therapeutics (TGTX), ImmunoGen (IMGN), Novavax (NVAX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Abeona Therapeutics (ABEO) and Energy Transfer LP Unit (ET).

Who are Protagonist Therapeutics' key executives?

Protagonist Therapeutics' management team includes the following people:
  • Dr. Dinesh V. Patel, CEO, Pres, Interim Principal Financial Officer, Interim PAO, Sec. & Director (Age 62)
  • Dr. Richard S. Shames, Chief Medical Officer (Age 59)
  • Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 69)
  • Dr. Mark Smythe, VP of Technology (Age 54)
  • Dr. Samuel R. Saks, Chief Devel. Officer (Age 64)

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets acted as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $15.17.

How big of a company is Protagonist Therapeutics?

Protagonist Therapeutics has a market capitalization of $416.11 million and generates $230,000.00 in revenue each year. The company earns $-77,190,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Protagonist Therapeutics employs 64 workers across the globe.

What is Protagonist Therapeutics' official website?

The official website for Protagonist Therapeutics is www.protagonist-inc.com.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.